Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue

Next Previous
Trial Profile

Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dinutuximab (Primary) ; Aldesleukin; Isotretinoin; Sargramostim; Sargramostim
  • Indications Neuroblastoma
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 15 Apr 2024 According to a Norgine media release, on 13 Dec 2023, the US Food and Drug Administration (FDA) approved eflornithine as the first oral maintenance therapy for high-risk neuroblastoma. The approval decision was based on findings from a trial comparing outcomes from Study 3b (NCT02395666; investigational arm) and Study ANBL0032 (NCT00026312; clinical-trial-derived external control arm).
    • 26 Oct 2023 Results of Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons (from studies NCT02395666, NCT00026312)published in the Journal of Clinical Oncology
    • 15 Jul 2022 Results (N=1183) published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top